Dyne Therapeutics, Inc. (DYN): R&D Expense
$398.33M
Year ended 2025-12-31
$445.82M
Trailing 12 months to 2026-06-30
+40.8%
3-year compound annual growth
+54.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $398.33M | +41.6% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $281.41M | +33.5% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $210.76M | +47.6% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $142.76M | +17.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $121.31M | +168.4% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $45.20M | +309.4% | 2022-03-10, From 2020-01-01 |
| 2019-12-31 | $11.04M | n/a | 2021-03-04, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | 2025-12-31 | $398.33M | +41.6% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $97.00M | -9.3% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $220.90M | -5.8% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $388.52M | +64.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $314.70M | +6.8% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $189.59M | +30.0% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $339.54M | +12.7% |
Compare DYN, INDV, ZLAB, RCUS side by side · Screen every company in Pharmaceutical Preparations ↗